JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Benefits of Metformin Use for Cholangiocarcinoma
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Benefits of Metformin Use for Cholangiocarcinoma
Kaewpitoon, Soraya J; Loyd, Ryan A; Rujirakul, Ratana; Panpimanmas, Sukij; Matrakool, Likit; Tongtawee, Taweesak; Kootanavanichpong, Nusorn; Kompor, Ponthip; Chavengkun, Wasugree; Kujapun, Jirawoot; Norkaew, Jun; Ponphimai, Sukanya; Padchasuwan, Natnapa; Pholsripradit, Poowadol; Eksanti, Thawatchai; Phatisena, Tanida; Kaewpitoon, Natthawut;
  PDF(new window)
 Abstract
Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus. It is purportedly associated with a reduced risk for various cancers, mainly exerting anti-proliferation effects on various human cancer cell types, such as pancreas, prostate, breast, stomach and liver. This mini-review highlights the risk and benefit of metformin used for cholangiocarcinoma (CCA) prevention and therapy. The results indicated metformin might be a quite promising strategy CCA prevention and treatment, one mechanism being inhibition of CCA tumor growth by cell cycle arrest in both in vitro and in vivo. The AMPK/mTORC1 pathway in intrahepatic CCA cells is targeted by metformin. Furthermore, metformin inhibited CCA tumor growth via the regulation of Drosha-mediated expression of multiple carcinogenic miRNAs. The use of metformin seems to be safe in patients with cirrhosis, and provides a survival benefit. Once hepatic malignancies are already established, metformin does not offer any therapeutic potential. Clinical trials and epidemiological studies of the benefit of metformin use for CCA should be conducted. To date, whether metformin as a prospective chemotherapeutic for CCA is still questionable and waits further atttention.
 Keywords
Metformin;cholangiocarcinoma;bile duct cancer;gall bladder cancer;
 Language
English
 Cited by
 References
1.
Akamatsu N, Sugawara Y, Hashimoto D (2011). Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol, 10, 94-107.

2.
Akinyeke T, Matsumura S, Wang X, et al (2013). Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis, 34, 2823-32. crossref(new window)

3.
Alimova IN, Liu B, Fan Z, et al (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 8, 909-15. crossref(new window)

4.
Bhargava P, Jani C, Savarese D, et al (2003). Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncol, 17, 23-6.

5.
Bhat A, Sebastiani G, Bhat M (2015). Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol, 7, 1652-9. crossref(new window)

6.
Bhat M, Sonenberg N, Gores GJ (2013). The mTOR pathway in hepatic malignancies. Hepatol, 58, 810-8. crossref(new window)

7.
Chaiteerakij R, Yang JD, Harmsen WS, et al (2013). Risk factors for intrahepatic cholangiocarcinoma: association be- tween metformin use and reduced cancer risk. Hepatol, 57, 648-55. crossref(new window)

8.
Chapman R (1999). Risk factors for biliary tract carcinogenesis. Ann Oncol, 10, 308-11. crossref(new window)

9.
Chang AH, Parsonnet J (2010). Role of bacteria in oncogenesis. Clin Microb Rev, 23, 837-7. crossref(new window)

10.
Choi C, Choi I, Seo J, et al (2000). Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol, 23, 425-8. crossref(new window)

11.
Dayton M, Longmire W, Tompkins R (1983). Caroli's Disease: a premalignant condition? Am J Surg, 145, 41-8. crossref(new window)

12.
Donato F, Gelatti U, Tagger A, et al (2001). Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control, 12, 959-64. crossref(new window)

13.
Giuliani F, Gebbia V, Maiello E, et al (2006). Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol, 17, 73-7.

14.
Green A, Uttaravichien T, Bhudhisawasdi V, et al. (1991). Cholangiocarcinoma in north east Thailand. A hospital-based study. Trop Geogr Med, 43, 193-8.

15.
Herrold KM (1967). Histogenesis of malignant liver tumors induced by dimethylnitrosamine. An experimental study in Syrian hamsters. J Natl Cancer Inst, 39, 1099-111.

16.
IARC. (1994). Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonrochis sinensis). IARC Monogr Eval Carcinog Risks of Hum, 61, 121-75.

17.
Jiang X, Ma N, Wang D, et al (2015). Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget, 6, 3178-94. crossref(new window)

18.
Jing W, Jin G, Zhou X, et al (2012). Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev, 21, 24-31. crossref(new window)

19.
Kato K, Gong J, Iwama H, et al (2012). The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther, 11, 549-60. crossref(new window)

20.
Knox J, Hedley D, Oza A, et al (2005). Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol, 23, 2332-8. crossref(new window)

21.
Landis S, Murray T, Bolden S, et al(1998). Cancer statistics, 1998. CA Cancer J Clin, 48, 6-29. crossref(new window)

22.
Lee S, Kim M, Lee S, et al (2004). Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer, 100, 783-93. crossref(new window)

23.
Lee C, Wu C, Chen G (2002). What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol, 17, 1015-20. crossref(new window)

24.
Ling S, Feng T, Ke Q, et al (2014). Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep, 31, 2611-8. crossref(new window)

25.
Lipsett P, Pitt H, Colombani P, et al (1994). Choledochal cyst disease. A changing pattern of presentation. Ann Surg, 220, 644-52. crossref(new window)

26.
Maksimova GA, Zhukova NA, Kashina EV, et al (2015). Role of Opisthorchis felineus on induction of bile duct cancer. Parazitologiia, 49, 3-11.

27.
Mecklin J, Jarvinen H, Virolainen M (1992). The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer, 69, 1112-4.

28.
Migasena P, Changbumrung S (1974). The role of nitrosamines in the cause of primary carcinoma. J Med Assoc Thai, 57, 175-8.

29.
Migasena P, Reaunsuwan W, Changbumrung S (1980). Nitrates and nitrites in local Thai preserved protein foods. J Med Assoc Thai, 63, 500-5.

30.
Mitacek EJ, Brunnemann KD, Hoffmann D, et al (1999). Volatile nitrosamines and tobacco- specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis, 20, 133-7. crossref(new window)

31.
Nair V, Pathi S, Jutooru I, et al (2013). Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis, 34, 2870-79. crossref(new window)

32.
Palmer WC, Patel T (2012). Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol, 57, 69-76. crossref(new window)

33.
Park J, Oh S, Kim S, et al (2005). Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol, 35, 68-73. crossref(new window)

34.
Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10. crossref(new window)

35.
Pernicova I, Korbonits M (2014). Metformin mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol, 10, 143-56. crossref(new window)

36.
Petrushev B, Tomuleasa C, Soritau O, et al (2012). Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol, 34, 17-24.

37.
Philip P, Mahoney M, Allmer C, et al (2006). Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol, 24, 3069-74. crossref(new window)

38.
Ren HB, Yu T, Liu C, et al (2011). Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes Control, 22, 837-47. crossref(new window)

39.
Rosen CB, Heimbach JK, Gores GJ (2008). Surgery for cholangiocarcinoma: the role of liver transplantation. Official J Inter Hepato Pancreato Biliary Assoc, 10, 186-9. crossref(new window)

40.
Saengboonmee C, Seubwai W, Wongkham C, et al (2015). Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma Association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol, 39, 274-278. crossref(new window)

41.
Sahani D, Prasad S, Tannabe K, et al (2003). Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging, 28, 72-4. crossref(new window)

42.
Shaib Y, El-Serag H, Davila J (2005). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterol, 128, 620-6. crossref(new window)

43.
Shin HR, Oh JK, Masuyer E, et al. (2010). Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci, 101, 579-85. crossref(new window)

44.
Sorensen H, Friis S, Olsen J, et al (1998). Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatol, 28, 921-5. crossref(new window)

45.
Sripa B, Yongvanit P, Pairojkul C (2005). Etiology and Pathogenesis of Cholangiocarcinoma: Introduction to the Association with Liver Fluke Infection. Srinagarind Med J, 20, 123-34

46.
Sripa B, Kaewkes S, Sithithaworn PM, et al. (2007). Liver fluke induces cholangiocarcinoma. PLoS Med, 4, 201. crossref(new window)

47.
Sripa B, Kaewkes S, Intapan PM, et al (2010). Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control. Adv Parasitol, 72, 305-350. crossref(new window)

48.
Su C, Shyr Y, Lui W, et al (1997). Hepatolithiasis associated with cholangiocarcinoma. Br J Surg, 84, 969-73. crossref(new window)

49.
Thamavit W, Bhamarapravati N, Sahaphong S, et al. (1978). Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res, 38, 4634-9.

50.
Thunyaharn N, Promthet S, Wiangnon S, et al (2013). Survival of cholangiocarcinoma patients in northeastern Thailand after supportive treatment. Asian Pac J Cancer Prev, 14, 7029-32. crossref(new window)

51.
Watanapa P, Watanapa W (2002). Liver fluke-associated cholangiocarcinoma. Br J Surg, 89, 962-70. crossref(new window)

52.
Yang Z, Zhang X, Roberts RO, et al (2015). Metformin does not improve survival of cholangiocarcinoma in persons with diabetes. Hepatol, 1.

53.
Yeo CJ, Pitt HA, Cameron JL (1990). Cholangiocarcinoma. Surg Clin North Am, 70, 1429-47. crossref(new window)

54.
Zhang LF, Zhao HX (2013). Diabetes mellitus and increased risk of extrahepatic cholangiocarcinoma: a meta-analysis. Hepatogastroenterol, 60, 684-7.

55.
Zhu A, Lauwers G, Tanabe K (2004). Cholangiocarcinoma in association with Thorotrast exposure. J Hepatobiliary Pancreat Surg, 11, 430-3. crossref(new window)